Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR)
19.88
-0.35 (-1.73%)
Arrowhead Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapeutics aimed at treating diseases through RNA interference (RNAi) technology
The company's primary goal is to create targeted treatments that can silence specific genes associated with various diseases, particularly in the areas of liver diseases, cancer, and cardiovascular conditions. Arrowhead's proprietary platform allows for the design of treatments that can effectively deliver small interfering RNA (siRNA) to relevant tissues, potentially leading to transformative therapies that address unmet medical needs. Through its research and development efforts, Arrowhead aims to advance its pipeline of drug candidates and bring novel solutions to the market for patients suffering from challenging health conditions.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a known pathway that signals the body to store fat in adipose tissue.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company’s Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company’s second investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead’s leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform.
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results.
Arrowhead Pharmaceuticals Inc. (NASDAQARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. NASDAQ: SRPTNASDAQSRPT)
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics NASDAQ: SRPTNASDAQSRPT)
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These data were presented in two oral presentations at the American Heart Association Scientific Sessions 2024 (AHA24) and PALISADE data was simultaneously published in the AHA journal, Circulation.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024.
Arrowhead Pharmaceuticals, Inc. (NASDAQARWR) today, on FCS Awareness Day, announced the launch of a new disease awareness campaign, 'We'll Get There Soon,' to bring hope to the rare disease community affected by Familial Chylomicronemia Syndrome (FCS). The campaign seeks to raise awareness about FCS, a severe and rare condition marked by persistently high triglyceride levels despite standard treatment, which can lead to serious and potentially life-threatening symptoms, including acute pancreatitis.
